In this most recent episode of “The Conversational Flow”, Adam and Brian dive into the flow-based Basophil Activation Test (BAT), explaining how it works, why it matters, and how it has evolved since basophils were first identified. They describe how BAT uses markers to assess basophil activation from a simple blood sample - offering a safer, more controlled alternative to in-vivo allergen challenges. The hosts highlight major obstacles to widespread adoption, including large protocol variations among labs across Europe and inconsistencies between commercially available kits, both of which make data hard to compare. They emphasize that BAT provides insights serum IgE tests alone cannot, helping clinicians and drug developers better predict hypersensitivity reactions, reduce risk, and pair diagnostic tools more intelligently. Throughout the discussion, Adam and Brian underscore the need for industry-wide standardization and thoughtful implementation to unlock the full value of BAT in clinical and drug-development environments.
“The Conversational Flow” an official podcast of KCAS Bio, and focuses on the more niche topic of Flow Cytometry and its role within the greater pharmaceutical, biopharmaceutical and bioanalytical industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Flow Cytometry experts as they chat over coffee and discuss what they’ve learned about the world of Flow Cytometry the past couple of weeks. “The Conversational Flow” is brought to you by KCAS Bio.
KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
